Blood Bank

ABO Blood Group System: Complete Guide to Blood Typing, Genetics, Forward & Reverse Grouping, ABO Discrepancies, and Clinical Significance

MedLabAcademy
Last update :
  
ABO Blood Group System: Complete Guide to Blood Typing, Genetics, Forward & Reverse Grouping, ABO Discrepancies, and Clinical Significance

 ABO Blood Typing (ABO Grouping)

ABO blood grouping is one of the most important laboratory procedures performed in transfusion medicine. The purpose of ABO typing is to accurately determine a patient's blood group before blood transfusion, organ transplantation, stem cell transplantation, or blood donation. To ensure maximum safety, two complementary tests are always performed:

  • Forward (Cell) Grouping
  • Reverse (Serum) Grouping

These two tests must agree with each other before a final ABO blood group is reported.

Forward and Reverse ABO Grouping

10. Principle of Forward (Cell) Grouping

Forward grouping identifies the ABO antigens present on the patient's red blood cells. The patient's RBCs are tested against commercially prepared antisera containing known antibodies.

If agglutination occurs, the corresponding antigen is present on the red blood cells.

Reagents Used

  • Anti-A
  • Anti-B
  • Anti-AB (optional)
  • Anti-D (for Rh typing)

Specimen Required

  • EDTA whole blood
  • Fresh sample (preferred)

11. Principle of Reverse (Serum) Grouping

Reverse grouping identifies the naturally occurring ABO antibodies present in the patient's serum or plasma.

Patient serum is mixed with reagent red blood cells of known blood groups (A cells and B cells).

Agglutination indicates the presence of the corresponding antibody.

Reagent Cells

  • A1 Cells
  • B Cells

12. Comparison Between Forward and Reverse Grouping

Feature Forward Grouping Reverse Grouping
Sample Used Patient RBCs Patient Serum/Plasma
Detects Antigens Antibodies
Reagents Anti-A & Anti-B A1 Cells & B Cells
Purpose Identify Blood Group Antigens Confirm Blood Group
Routine Use Mandatory Mandatory

13. Forward Grouping Procedure (Tube Method)

  1. Label four tubes (Anti-A, Anti-B, Anti-AB, Control).
  2. Add one drop of each reagent.
  3. Add one drop of 2–5% patient red cell suspension.
  4. Mix gently.
  5. Centrifuge according to laboratory SOP.
  6. Resuspend the cell button.
  7. Observe for agglutination.
  8. Grade the reaction.
Tube Method ABO Grouping

14. Reverse Grouping Procedure

  1. Label tubes A1 Cells and B Cells.
  2. Add two drops of patient serum.
  3. Add one drop of reagent red cells.
  4. Mix thoroughly.
  5. Centrifuge.
  6. Resuspend gently.
  7. Read agglutination macroscopically.
  8. Confirm microscopically if necessary.

15. Interpretation of Forward Grouping

Anti-A Anti-B Blood Group
+ - A
- + B
+ + AB
- - O

16. Interpretation of Reverse Grouping

A1 Cells B Cells Blood Group
- + A
+ - B
- - AB
+ + O

17. Final ABO Interpretation

The patient's blood group is reported only after the forward grouping result agrees perfectly with the reverse grouping result.

Forward Reverse Final Report
A A Blood Group A
B B Blood Group B
AB AB Blood Group AB
O O Blood Group O

18. Grading of Agglutination

Grade Description
4+ One large solid agglutinate with clear background
3+ Several large agglutinates with clear background
2+ Medium-sized agglutinates with some free cells
1+ Small agglutinates with many free cells
W+ Weak tiny agglutinates
0 No agglutination

19. Quality Control

  • Use reagents before expiration date.
  • Store antisera at recommended temperatures.
  • Run positive and negative controls daily.
  • Verify reagent cell integrity.
  • Reject hemolyzed or contaminated specimens.
  • Follow laboratory SOPs strictly.
  • Document all QC results.

20. Common Technical Errors

Error Possible Effect
Incorrect cell suspension Weak or false reactions
Expired antisera False-negative results
Improper centrifugation Weak agglutination
Dirty glassware False-positive reactions
Specimen mix-up Wrong blood group reporting
Reading reactions too late Misinterpretation

Key Points

  • Forward grouping detects RBC antigens.
  • Reverse grouping detects plasma antibodies.
  • Both tests must always agree.
  • ABO typing is the first and most critical step before blood transfusion.
  • Any discrepancy must be investigated before reporting the final blood group.

Next Part: ABO Discrepancies, Weak Subgroups, Bombay Phenotype, Resolution of Discrepancies, Clinical Cases, and Troubleshooting.

21. ABO Discrepancies

An ABO discrepancy occurs when the results of forward (cell) grouping and reverse (serum) grouping do not agree. Since both tests should produce complementary results, any disagreement must be investigated before reporting the patient's blood group.

Golden Rule:
Never issue an ABO blood group result until the discrepancy has been completely resolved.
ABO Discrepancies Flowchart

22. Classification of ABO Discrepancies

ABO discrepancies are traditionally divided into four major groups.

Group Main Cause Typical Problem
Group I Weak or missing antibodies Reverse grouping
Group II Weak or missing antigens Forward grouping
Group III Protein or plasma abnormalities Pseudoagglutination
Group IV Miscellaneous causes Unexpected reactions

23. Group I Discrepancies (Weak or Missing Antibodies)

These discrepancies occur when naturally occurring ABO antibodies are absent or weaker than expected, resulting in weak or negative reactions during reverse grouping.

Common Causes

  • Newborn infants
  • Elderly patients
  • Immunodeficiency disorders
  • Hypogammaglobulinemia
  • Bone marrow transplantation
  • Massive transfusion
  • Immunosuppressive therapy

Resolution

  • Repeat reverse grouping.
  • Increase serum-to-cell ratio.
  • Incubate at room temperature (15–30 minutes).
  • Review patient history.

24. Group II Discrepancies (Weak or Missing Antigens)

These occur when red blood cells express reduced amounts of A or B antigen, producing weak reactions during forward grouping.

Common Causes

  • Weak A subgroups
  • Weak B subgroups
  • Acute leukemia
  • Hematologic malignancies
  • Recent stem cell transplantation
  • Mixed-field populations

Resolution

  • Repeat testing with fresh cells.
  • Use Anti-A,B reagent.
  • Perform adsorption-elution studies.
  • Use anti-A1 lectin.
  • Use anti-H lectin.

25. Group III Discrepancies (Protein Abnormalities)

These discrepancies result from abnormal plasma proteins that produce rouleaux formation, mimicking agglutination.

Common Causes

  • Multiple myeloma
  • Waldenström macroglobulinemia
  • High fibrinogen levels
  • Plasma expanders

Resolution

  • Perform saline replacement technique.
  • Wash red blood cells thoroughly.
  • Repeat testing.

26. Group IV Discrepancies

These include miscellaneous conditions that produce unexpected reactions.

Examples

  • Cold autoantibodies
  • Cold alloantibodies
  • Bombay phenotype
  • Unexpected antibodies
  • Polyagglutination
  • Recent transfusion
  • Chimerism

27. Weak A Subgroups

Weak A subgroups express fewer A antigens than normal Group A cells.

Subtype Frequency Characteristics
A1 ≈80% Strong antigen expression
A2 ≈20% Slightly weaker expression
A3 Rare Mixed-field agglutination
Ax Very rare Weak Anti-A reaction
Am Extremely rare Detected mainly by adsorption-elution

28. A1 vs A2 Blood Groups

Feature A1 A2
Antigen Density High Lower
Anti-A1 Lectin Positive Negative
Anti-H Lectin Weak Stronger
Anti-A1 Antibody Absent May be present

29. Bombay Phenotype (Oh)

The Bombay phenotype is an extremely rare blood group caused by the complete absence of the H antigen. Without the H antigen, neither A nor B antigens can be produced.

Although Bombay individuals may appear as Group O by routine testing, they possess potent anti-H antibodies and cannot safely receive ordinary Group O blood.
Feature Bombay Phenotype
H Antigen Absent
A Antigen Absent
B Antigen Absent
Anti-H Antibody Present
Compatible Blood Bombay only
Bombay Blood Group

30. Mixed-Field Agglutination

Mixed-field agglutination is characterized by two distinct cell populations: one agglutinated and one free.

Common Causes

  • Recent blood transfusion
  • Stem cell transplantation
  • A3 subgroup
  • Chimerism

31. Investigation of ABO Discrepancies

  1. Repeat both forward and reverse grouping.
  2. Check patient identification.
  3. Review clinical history.
  4. Inspect specimen quality.
  5. Wash red blood cells.
  6. Repeat using fresh reagents.
  7. Perform microscopic examination.
  8. Use Anti-A1 lectin.
  9. Use Anti-H lectin.
  10. Perform antibody screening if required.
  11. Consider molecular genotyping in unresolved cases.

32. Clinical Case Example

Case: A 72-year-old patient demonstrates:
  • Forward Grouping: Anti-A = 4+, Anti-B = Negative
  • Reverse Grouping: A1 Cells = Negative, B Cells = Weak (1+)
Interpretation: Weak anti-B antibody due to advanced age (Group I discrepancy).

33. Laboratory Tips

  • Never ignore weak reactions.
  • Compare current and previous blood group records.
  • Review transfusion history.
  • Review transplant history.
  • Document all discrepancy investigations.
  • Consult the transfusion medicine specialist when necessary.

Key Points

  • Every ABO discrepancy must be resolved before reporting.
  • Group I involves weak antibodies.
  • Group II involves weak antigens.
  • Bombay phenotype lacks the H antigen.
  • Mixed-field reactions often indicate two RBC populations.
  • Patient history is essential for discrepancy resolution.

Next Part (Part 4): ABO Compatibility, Blood Transfusion, Universal Donors and Recipients, Hemolytic Transfusion Reactions, Massive Transfusion, Neonatal Considerations, Organ Transplantation, Case Studies, and Clinical Applications.

34. ABO Compatibility in Blood Transfusion

The primary goal of blood transfusion is to provide compatible blood that will not trigger an immune reaction in the recipient. Because naturally occurring ABO antibodies are mainly IgM and efficiently activate complement, transfusing ABO-incompatible blood may result in severe intravascular hemolysis, disseminated intravascular coagulation (DIC), renal failure, shock, and death.

ABO Blood Transfusion Compatibility Chart

35. Why ABO Compatibility Is Essential

When donor red blood cells carry an antigen against which the recipient has antibodies, rapid agglutination and hemolysis occur. This is considered a medical emergency and requires immediate recognition and intervention.

Remember: Even a small volume of ABO-incompatible blood may cause a life-threatening transfusion reaction.

36. Red Blood Cell (RBC) Compatibility

Recipient Blood Group Compatible RBC Units
Group O O only
Group A A or O
Group B B or O
Group AB AB, A, B, or O

37. Plasma Compatibility

Plasma compatibility differs from red cell compatibility because the donor plasma contains antibodies.

Recipient Compatible Plasma
O O, A, B, AB
A A or AB
B B or AB
AB AB only

38. Universal Donors and Universal Recipients

Component Universal Donor Universal Recipient
Red Blood Cells O Negative AB Positive
Plasma AB Plasma Group O
Clinical Note: O Negative blood is reserved whenever possible for emergency situations because of its limited availability.

39. Emergency Blood Transfusion

If there is insufficient time to determine the patient's blood group, emergency uncrossmatched blood may be issued according to institutional policy.

Patient Recommended Blood
Adult Female of Childbearing Age O Rh Negative
Adult Male O Negative or O Positive (depending on policy)
Pediatric Patient O Rh Negative

40. Acute Hemolytic Transfusion Reaction (AHTR)

Acute hemolytic transfusion reaction is one of the most serious transfusion complications and is most commonly caused by ABO incompatibility.

Clinical Features

  • Fever
  • Chills
  • Hypotension
  • Back pain
  • Chest pain
  • Hemoglobinuria
  • Renal failure
  • DIC
  • Shock

41. Immediate Laboratory Investigation

  1. Stop the transfusion immediately.
  2. Verify patient identification.
  3. Notify the blood bank.
  4. Repeat ABO and Rh typing.
  5. Repeat crossmatch.
  6. Perform Direct Antiglobulin Test (DAT).
  7. Inspect plasma for hemolysis.
  8. Measure bilirubin and LDH.
  9. Check haptoglobin.
  10. Examine urine for hemoglobin.

42. Causes of ABO-Incompatible Transfusion

Cause Frequency
Patient identification error Very Common
Sample labeling error Common
Wrong blood issued Less Common
Clerical error Common
Failure to follow SOP Preventable

43. Massive Transfusion

Massive transfusion is generally defined as replacement of one blood volume within 24 hours or transfusion of 10 or more units of packed red blood cells in an adult.

When the patient's ABO type is confirmed, transfusion should be switched to ABO-identical blood whenever possible.

44. Neonatal ABO Considerations

Newborn infants have immature immune systems and therefore produce little or no naturally occurring ABO antibodies.

  • Forward grouping is reliable.
  • Reverse grouping is usually not performed before four months of age.
  • Maternal antibodies may influence neonatal testing.

45. ABO Hemolytic Disease of the Newborn (ABO-HDN)

ABO Hemolytic Disease of the Newborn usually occurs when a Group O mother carries a fetus with Group A or Group B blood.

Feature ABO-HDN
Mother Usually Group O
Infant Group A or B
Severity Usually Mild
Common Finding Neonatal Jaundice

46. ABO Compatibility in Organ Transplantation

ABO compatibility is essential for successful transplantation of many solid organs, especially kidneys, hearts, and lungs.

ABO incompatibility may result in hyperacute rejection due to preformed recipient antibodies.

47. Clinical Case Study

Case: A 58-year-old male with blood group B accidentally received one unit of Group A packed red blood cells.

Clinical Findings:
  • Fever within 15 minutes
  • Severe back pain
  • Hypotension
  • Dark urine
Laboratory Findings:
  • Positive DAT
  • Hemoglobinemia
  • Hemoglobinuria
  • Elevated LDH
  • Low Haptoglobin
Diagnosis: Acute ABO-Incompatible Hemolytic Transfusion Reaction.

48. Practical Tips for Medical Laboratory Professionals

  • Always verify patient identity before collecting the sample.
  • Never rely on previous blood group records alone.
  • Perform both forward and reverse grouping.
  • Investigate every unexpected reaction.
  • Follow institutional SOPs.
  • Document all transfusion-related incidents.
  • Report suspected transfusion reactions immediately.

Key Points

  • ABO compatibility is the most important requirement before transfusion.
  • ABO incompatibility may cause fatal intravascular hemolysis.
  • O Negative is the universal RBC donor.
  • AB Positive is the universal RBC recipient.
  • AB plasma is the universal plasma donor.
  • Patient identification errors remain the leading cause of ABO mismatches.
  • Immediate investigation is mandatory whenever a transfusion reaction is suspected.

Next Part (Part 5 – Final): Advanced Blood Bank Techniques, Automation in ABO Typing, Molecular ABO Genotyping, Quality Assurance, Common Examination Questions, Clinical Pearls, References (AABB, ISBT, WHO), FAQ Schema, and Conclusion.

49. Modern Methods for ABO Blood Grouping

Although the traditional tube method remains the reference technique in many laboratories, modern blood banks increasingly use automated technologies that improve accuracy, standardization, and turnaround time.

Method Advantages Limitations
Slide Method Rapid screening Not recommended for final reporting
Tube Method Gold standard, inexpensive Operator dependent
Gel Card Technology High sensitivity, standardized, easy interpretation Higher cost
Solid Phase Technology Excellent automation and reproducibility Requires specialized equipment
Fully Automated Blood Bank Analyzer High throughput, barcode verification, minimal human error High installation and maintenance cost

50. Gel Card Technology

Gel technology has become one of the most widely used methods in modern transfusion laboratories. Instead of observing agglutination directly in a tube, red blood cells migrate through a gel matrix during centrifugation.

  • Positive reactions remain trapped within the gel.
  • Negative reactions form a pellet at the bottom of the microtube.
  • Provides excellent reproducibility.
  • Ideal for blood grouping, antibody screening, and compatibility testing.
Gel Card Technology

51. Molecular ABO Genotyping

Molecular testing identifies ABO alleles by analyzing DNA rather than red cell antigens. It is particularly useful when serologic results are inconclusive.

Clinical Applications

  • Resolving ABO discrepancies.
  • Weak A or B subgroups.
  • Recently transfused patients.
  • Stem cell transplant recipients.
  • Prenatal investigations.
  • Rare blood group identification.

52. Quality Assurance (QA) in ABO Testing

Quality assurance ensures that every blood grouping result is accurate, reliable, and traceable.

Essential QA Components

  • Written Standard Operating Procedures (SOPs).
  • Competency assessment of staff.
  • Equipment calibration and maintenance.
  • Participation in External Quality Assessment (EQA).
  • Document control.
  • Risk management.
  • Incident reporting.
  • Continuous quality improvement.

53. Internal Quality Control (IQC)

Quality Control Item Frequency
Reagent inspection Daily
Positive control Daily
Negative control Daily
Temperature monitoring Daily
Centrifuge verification Scheduled
Pipette calibration Periodic

54. Common Pitfalls in ABO Testing

  • Incorrect patient identification.
  • Improper specimen labeling.
  • Hemolyzed or clotted specimens.
  • Improper reagent storage.
  • Failure to perform reverse grouping.
  • Ignoring weak reactions.
  • Reporting unresolved discrepancies.
  • Using expired reagents.
  • Poor documentation.

55. Clinical Pearls

  • Always perform both forward and reverse grouping in adults.
  • Never report an unresolved ABO discrepancy.
  • Patient identification is more important than the testing method itself.
  • The majority of fatal transfusion reactions are caused by human error rather than laboratory reagents.
  • Every unexpected result deserves investigation.
  • Maintain complete documentation for traceability.

56. Frequently Asked Questions (FAQ)

Can Group O receive blood from Group A?

No. Group O individuals possess both Anti-A and Anti-B antibodies and can receive only Group O red blood cells.

Why is Group AB called the universal recipient?

Because individuals with Group AB have neither Anti-A nor Anti-B antibodies in their plasma.

Why is O Negative considered the universal donor?

O Negative red blood cells lack A, B, and Rh(D) antigens, making them suitable for emergency transfusion when the patient's blood type is unknown.

Can ABO typing be affected after stem cell transplantation?

Yes. Blood group changes may occur depending on donor engraftment, requiring careful interpretation and follow-up testing.

57. Summary

The ABO Blood Group System remains the foundation of transfusion medicine and immunohematology. Accurate blood grouping depends on correct specimen identification, proper laboratory technique, quality control, and careful interpretation of both forward and reverse grouping results. Modern technologies such as gel card systems, automation, and molecular genotyping have significantly improved the reliability of ABO testing, but they do not replace sound laboratory practice or clinical judgment.

58. Key Take-Home Messages

  • ABO is the most clinically significant blood group system.
  • Always perform both forward and reverse grouping.
  • Resolve every discrepancy before reporting.
  • Follow SOPs and quality assurance requirements.
  • Patient identification is critical to transfusion safety.
  • Automation improves efficiency but does not eliminate the need for professional oversight.

59. References

  1. AABB. Standards for Blood Banks and Transfusion Services. Latest Edition.
  2. AABB Technical Manual. Latest Edition.
  3. CLSI. GP41 Collection of Diagnostic Blood Specimens.
  4. CLSI. Transfusion Medicine Guidelines.
  5. International Society of Blood Transfusion (ISBT). Blood Group Terminology.
  6. World Health Organization (WHO). Blood Transfusion Safety.
  7. Harmening DM. Modern Blood Banking and Transfusion Practices.
  8. Roback JD. Technical Manual of Blood Banking.
  9. Dean L. Blood Groups and Red Cell Antigens. NCBI Bookshelf.
  10. British Society for Haematology (BSH). Guidelines for Pre-transfusion Compatibility Procedures.

60. Conclusion

Understanding the ABO Blood Group System is essential for every medical laboratory professional. From routine blood typing to resolving complex discrepancies and supporting safe transfusion practices, mastery of ABO principles directly contributes to patient safety and high-quality laboratory services. Continuous education, adherence to international standards, and commitment to quality are the cornerstones of excellence in transfusion medicine.

Prepared by

Dr. Omar Adwan
Medical Laboratory Technologist
Founder of MedLab Academy
Dedicated to advancing medical laboratory education through evidence-based, practical, and clinically relevant learning resources.

61. ABO and Rh Blood Compatibility

ABO compatibility and Rh compatibility must both be considered when selecting red blood cell units for transfusion. The ABO system is the most immediately important because incompatible naturally occurring antibodies can cause rapid intravascular hemolysis. Rh(D) compatibility is also important, particularly for females of childbearing potential, pediatric patients, and individuals who may require repeated transfusions.

Important: The table below is a general educational guide for red blood cell transfusion. Actual component selection must follow the blood bank’s validated procedures, crossmatch results, patient history, antibody screen, and institutional emergency-release policy.

61.1 ABO and Rh-Compatible Red Blood Cells

Recipient Blood Group Compatible Red Blood Cell Units Preferred Choice
O Negative O Negative O Negative
O Positive O Positive or O Negative O Positive
A Negative A Negative or O Negative A Negative
A Positive A Positive, A Negative, O Positive, or O Negative A Positive
B Negative B Negative or O Negative B Negative
B Positive B Positive, B Negative, O Positive, or O Negative B Positive
AB Negative AB Negative, A Negative, B Negative, or O Negative AB Negative
AB Positive AB Positive, AB Negative, A Positive, A Negative, B Positive, B Negative, O Positive, or O Negative AB Positive
Clinical Pearl: AB Positive individuals are often described as universal recipients of red blood cells, but transfusion services generally prefer ABO-identical components whenever they are available.

61.2 Plasma Compatibility

Plasma compatibility follows a pattern that appears opposite to red blood cell compatibility because the clinically relevant substances in plasma are donor antibodies rather than donor red cell antigens.

Recipient Blood Group Compatible Plasma Explanation
Group O O, A, B, or AB plasma Group O red cells lack A and B antigens.
Group A A or AB plasma Plasma must not contain clinically significant anti-A.
Group B B or AB plasma Plasma must not contain clinically significant anti-B.
Group AB AB plasma AB red cells express both A and B antigens.

61.3 Universal Donor and Recipient Concepts

Blood Component Universal Donor Universal Recipient Important Qualification
Red Blood Cells O Negative AB Positive Compatibility testing and antibody history must still be considered.
Plasma AB Plasma Group O Local policies may permit other low-titer plasma strategies in emergencies.
Blood Bank Practice: Group-specific or ABO-identical components are usually preferred because they preserve limited universal-donor inventory and reduce unnecessary exposure to incompatible plasma antibodies.

62. Biochemical Formation of ABO Antigens

ABO antigens are carbohydrate structures formed by the sequential activity of specific glycosyltransferase enzymes. The precursor structure is first modified to produce the H antigen. The A or B transferase then modifies the H antigen to form the A or B antigen.

62.1 The H Antigen Pathway

Precursor Oligosaccharide Chain ↓ FUT1 Gene Encodes an α-1,2-Fucosyltransferase ↓ Formation of the H Antigen ↓
A Allele
Adds N-acetylgalactosamine
↓
A Antigen B Allele
Adds D-galactose
↓
B Antigen
↓ O Allele: No Functional A or B Transferase
H Antigen Remains Unmodified
Key Concept: The O blood group is not completely antigen-free. Group O red cells usually express abundant H antigen because it is not converted into A or B antigen.

62.2 Enzymes and Terminal Sugars

Blood Group Functional Enzyme Terminal Sugar Added Final Antigen
Group A A glycosyltransferase N-acetylgalactosamine A antigen
Group B B glycosyltransferase D-galactose B antigen
Group AB Both A and B transferases Both terminal sugars A and B antigens
Group O No functional A or B transferase No additional terminal sugar Unmodified H antigen

62.3 Relative H Antigen Expression

The amount of detectable H antigen varies according to how much of it has been converted into A or B antigen. In general, Group O cells express the greatest amount of H antigen, while A1B cells express relatively little.

Blood Group Relative H Antigen Expression
O Highest
A2 High
B Moderate to high
A2B Moderate
A1 Lower
A1B Lowest among common ABO phenotypes

63. Anti-H Lectin

Anti-H lectin is a plant-derived reagent used to detect the H antigen on red blood cells. It is commonly prepared from Ulex europaeus seeds and is particularly useful when investigating suspected Bombay phenotype or differentiating patterns of H antigen expression.

63.1 Main Uses of Anti-H Lectin

  • Detecting H antigen on red blood cells.
  • Supporting investigation of suspected Bombay phenotype.
  • Comparing relative H expression in A1 and A2 cells.
  • Investigating unusual or weak ABO reactions.
  • Supporting classification of selected ABO subgroups.

63.2 Expected Anti-H Reactions

Red Cell Type Expected Anti-H Reaction Interpretation
Group O Cells Strong Positive Large amount of unmodified H antigen.
A2 Cells Moderate to Strong Positive More H antigen remains than on A1 cells.
B Cells Positive H antigen is present beneath B antigen expression.
A1 Cells Weak Positive More H antigen has been converted to A antigen.
Bombay Phenotype Cells Negative H antigen is absent.
Critical Warning: A person with the Bombay phenotype may appear to be Group O during routine forward typing. However, the individual lacks H antigen and may produce potent anti-H. Ordinary Group O blood is therefore not compatible.

63.3 Bombay Phenotype Versus Group O

Feature Ordinary Group O Bombay Phenotype (Oh)
A Antigen Absent Absent
B Antigen Absent Absent
H Antigen Strongly Present Absent
Anti-A Present Usually Present
Anti-B Present Usually Present
Anti-H Usually Absent Present
Reaction with Anti-H Lectin Strong Positive Negative
Compatible RBC Units Group O Bombay phenotype only
Clinical Pearl: A strong reaction against screening cells or Group O cells, combined with an apparent Group O forward type, should prompt consideration of anti-H and the Bombay phenotype.

64. ABO Subgroups

ABO subgroups are inherited variations characterized by quantitative or qualitative differences in A or B antigen expression. Most subgroup-related discrepancies involve weak A phenotypes because A subgroups are more commonly recognized than weak B subgroups.

Laboratory investigation may include:

  • Reaction strength with anti-A and anti-B.
  • Reaction with anti-A,B.
  • Testing with anti-A1 lectin.
  • Testing with anti-H lectin.
  • Reverse grouping.
  • Saliva secretor studies when appropriate.
  • Adsorption and elution procedures.
  • Molecular ABO genotyping.

64.1 Common A Subgroups

A Subgroup Typical Anti-A Reaction Anti-A,B Reaction Anti-A1 Lectin Typical Characteristics
A1 Strong Strong Positive Most common A phenotype with high A antigen density.
A2 Strong Strong Negative Lower antigen density than A1; some individuals may form anti-A1.
A3 Mixed-field Mixed-field or stronger Usually Negative Characteristic mixture of agglutinated and unagglutinated cells.
Ax Weak or Negative Often Positive Negative Anti-A,B may react more strongly than anti-A.
Am Usually Negative Usually Negative Negative A antigen may require adsorption-elution for detection.
Ael Negative Negative Negative Extremely weak A expression, often detected only by adsorption-elution or genotyping.
Aint Variable Positive Variable Intermediate characteristics between A1 and A2.

64.2 A1 Versus A2

Feature A1 A2
Relative Frequency Among Group A Individuals More common Less common
A Antigen Density Higher Lower
Reaction with Anti-A Strong Strong
Reaction with Anti-A1 Lectin Positive Negative
Reaction with Anti-H Lectin Weaker Stronger
Potential Anti-A1 Formation Not Expected May Occur
Anti-A1: Some A2 and A2B individuals may produce anti-A1. Its clinical significance depends on reactivity characteristics, including whether it reacts at temperatures relevant to transfusion.

64.3 Typical Serologic Patterns of Weak A Subgroups

Subgroup Anti-A Anti-A,B Anti-A1 Lectin Anti-H Reverse Grouping
A1 4+ 4+ Positive Weak Expected anti-B
A2 4+ 4+ Negative Stronger than A1 Anti-B; possible anti-A1
A3 Mixed-field Mixed-field Usually Negative Positive Usually anti-B
Ax Weak or Negative Weak Positive Negative Positive Anti-B; anti-A1 may be present
Am Negative Negative Negative Positive Anti-B usually present
Ael Negative Negative Negative Positive May appear Group O serologically
Interpretation Warning: Serologic reaction strengths may vary according to reagent formulation, testing platform, temperature, technique, specimen condition, and the specific inherited allele. Final classification should not depend on one reaction alone.

64.4 Weak B Subgroups

Weak B subgroups are less commonly encountered than weak A subgroups. They may produce reduced or variable reactions with anti-B and can create discrepancies between forward and reverse grouping.

B Subgroup Typical Serologic Pattern Important Features
B3 Mixed-field reaction with anti-B Two visible red cell populations may be observed.
Bx Weak reaction with anti-B and often stronger reaction with anti-A,B Reverse grouping may show anti-A; additional studies may be required.
Bm Little or no direct agglutination with anti-B B antigen may be demonstrable by adsorption-elution; B substance may be present in saliva in secretors.
Bel Extremely weak or undetectable by routine serology Molecular methods or specialized serologic techniques may be necessary.

64.5 Acquired B Phenomenon

Acquired B is not an inherited B subgroup. It is an acquired modification that may occur in some Group A individuals, particularly in association with certain gastrointestinal conditions or bacterial enzymatic activity. The modified A antigen may react weakly with some anti-B reagents, causing an apparent AB forward type.

Feature Acquired B True Group AB
Underlying ABO Group Usually Group A Inherited Group AB
Anti-B Reaction Usually weak or reagent-dependent Usually strong
Reverse Grouping Often shows expected anti-B for Group A No expected anti-A or anti-B
Patient History May include gastrointestinal disease, infection, or obstruction No acquired clinical cause required
Clinical Pearl: An apparent AB result in forward grouping with anti-B detected during reverse grouping should not be reported as AB until acquired B, subgroup expression, cold antibodies, and technical errors have been investigated.

65. Cis-AB Phenotype

The Cis-AB phenotype is a rare inherited ABO variant in which one allele can encode an enzyme capable of producing both A-like and B-like antigen activity. Because the A and B characteristics are inherited together on the same chromosome, family studies may appear inconsistent with ordinary ABO inheritance.

65.1 Why Cis-AB Is Important

  • It may produce weak or unusual B antigen expression.
  • Forward and reverse grouping may not show a classic AB pattern.
  • Family inheritance patterns may appear unexpected.
  • It can be confused with acquired B or another weak subgroup.
  • Molecular genotyping may be required for definitive classification.

65.2 Possible Laboratory Findings

Test Possible Finding
Anti-A Strong or moderately strong reaction
Anti-B Weak or variable reaction
Anti-A,B Positive
Reverse Grouping May contain weak anti-B or another unexpected reaction
Family Study A and B characteristics may be inherited together
ABO Genotyping Useful for confirmation
Interpretation: Cis-AB should be considered when unusual A/B expression is accompanied by an inheritance pattern that cannot be explained by ordinary A, B, and O alleles.

66. Laboratory Approach to Suspected ABO Subgroups

  1. Confirm patient identification and specimen labeling.
  2. Repeat forward and reverse grouping using a freshly prepared cell suspension.
  3. Wash the patient’s red blood cells at least three times when appropriate.
  4. Review reaction grades carefully and look for mixed-field agglutination.
  5. Test with anti-A,B reagent.
  6. Use anti-A1 lectin when an A subgroup is suspected.
  7. Use anti-H lectin to assess H antigen expression.
  8. Review previous blood group records.
  9. Review recent transfusion and stem cell transplantation history.
  10. Assess for cold-reactive antibodies or autoagglutination.
  11. Perform adsorption-elution studies when indicated.
  12. Consider saliva inhibition studies in secretors when appropriate.
  13. Perform molecular ABO genotyping if serologic testing remains inconclusive.
  14. Consult a transfusion medicine specialist before final reporting.

85. Compatibility Testing and Crossmatching

Compatibility testing is performed before red blood cell transfusion to reduce the risk of transfusing incompatible donor cells. It combines patient identification, ABO and RhD typing, antibody screening, donor unit selection, and crossmatching.

The crossmatch is the final serologic or electronic verification step before a red blood cell unit is issued. It helps confirm ABO compatibility and may detect antibodies that react with antigens present on the selected donor red cells.

Critical Safety Principle

A technically correct crossmatch cannot compensate for incorrect patient identification, mislabeled specimens, wrong historical records, or failure to investigate a clinically significant antibody.

86. Objectives of Pretransfusion Testing

  • Confirm the identity of the patient and the collected specimen.
  • Determine the patient's ABO and RhD blood group.
  • Detect clinically significant red cell antibodies.
  • Select ABO-compatible and antigen-appropriate donor units.
  • Confirm compatibility between patient plasma and donor red cells.
  • Prevent acute and delayed hemolytic transfusion reactions.
  • Maintain full traceability from sample collection to component issue.

87. Components of Pretransfusion Testing

Patient Identification

Confirm the patient's full name, identification number, date of birth, wristband details, and specimen label according to institutional policy.

ABO and RhD Typing

Perform forward ABO grouping, reverse ABO grouping where appropriate, and RhD typing using validated reagents and procedures.

Antibody Screen

Test patient plasma against reagent screening cells that express clinically important red cell antigens.

Crossmatch

Test or electronically verify compatibility between the patient's plasma and the selected donor red blood cells.

88. Major Crossmatch

The major crossmatch tests the patient's serum or plasma against red blood cells from the selected donor unit.

Major Crossmatch Formula

Patient serum or plasma + donor red blood cells

The major crossmatch is designed to identify incompatibility caused by recipient antibodies reacting with donor red cell antigens.

89. What the Major Crossmatch Can Detect

  • ABO incompatibility.
  • Some clinically significant alloantibodies.
  • Some unexpected serologic incompatibilities.
  • Selection of an unsuitable antigen-positive donor unit.
  • Errors involving the wrong donor segment or wrong patient plasma.

90. Limitations of the Major Crossmatch

  • It cannot reliably prevent errors caused by wrong patient identification.
  • It may not detect antibodies below the sensitivity of the method.
  • It does not replace the antibody screen.
  • It may not detect donor red cell antigens expressed weakly.
  • It does not guarantee prevention of every delayed hemolytic reaction.
  • It does not detect antibodies against platelets, leukocytes, or plasma proteins.

91. Minor Crossmatch

The minor crossmatch historically tested donor serum or plasma against patient red blood cells.

Minor Crossmatch Formula

Donor serum or plasma + patient red blood cells

Routine minor crossmatching is generally not part of modern pretransfusion testing for packed red blood cells because most donor plasma is removed, donors are tested for clinically relevant antibodies according to blood center procedures, and component preparation reduces the amount of incompatible plasma.

Historical Method

The minor crossmatch is mainly taught to explain the historical development of compatibility testing. Plasma-containing components must still be selected according to ABO compatibility and institutional policy.

92. Types of Crossmatch

Crossmatch Type Main Purpose Typical Use Major Limitation
Immediate-Spin Crossmatch Detect ABO incompatibility Patients with a negative antibody screen and no history of clinically significant antibodies Does not reliably detect all clinically significant IgG antibodies
Antiglobulin Crossmatch Detect clinically significant antibodies reacting at the antiglobulin phase Patients with current or historical clinically significant antibodies Requires more time and additional testing
Electronic Crossmatch Computer verification of ABO compatibility without serologic mixing Eligible patients in validated laboratory information systems Requires strict validation, secure data, and eligibility criteria
Emergency Release Provide blood before routine testing is completed Life-threatening bleeding or urgent transfusion Compatibility testing may be incomplete at the time of issue

93. Immediate-Spin Crossmatch

The immediate-spin crossmatch is a rapid test designed mainly to detect ABO incompatibility between patient plasma and donor red cells.

94. General Immediate-Spin Procedure

  1. Verify patient and donor unit identification.
  2. Label the test tube according to laboratory SOP.
  3. Add the required volume of patient serum or plasma.
  4. Add donor red cells prepared from the attached donor segment.
  5. Mix thoroughly.
  6. Centrifuge immediately using the validated setting.
  7. Resuspend the cell button gently.
  8. Inspect for hemolysis and agglutination.
  9. Record and interpret the result.
Observation Interpretation Action
No agglutination and no hemolysis Compatible at immediate-spin phase Unit may be eligible for issue if all other requirements are satisfied
Agglutination Incompatible Do not issue; investigate ABO grouping, specimen identity, and antibodies
Visible hemolysis Potential incompatibility or specimen problem Investigate before interpretation or unit issue
Eligibility Requirement

Immediate-spin crossmatching is generally limited to patients whose current antibody screen is negative and who have no history of clinically significant red cell antibodies.

95. Antiglobulin Crossmatch

The antiglobulin crossmatch is performed through an indirect antiglobulin test phase. It is used when a patient has a current or historical clinically significant antibody or when laboratory policy requires a full serologic crossmatch.

96. General Antiglob

119. Sources of Error in ABO Blood Grouping

Errors in ABO testing may occur before, during, or after the analytical procedure. Because an incorrect ABO result can lead to a life-threatening transfusion reaction, every stage of testing must be controlled, documented, and reviewed.

Laboratory errors are commonly divided into three major categories:

  • Pre-analytical errors occurring before testing begins.
  • Analytical errors occurring during the test procedure.
  • Post-analytical errors occurring during interpretation, reporting, or communication.
Most Important Safety Principle

Correct patient identification and correct specimen labeling are more important than the complexity of the testing method. Even perfect laboratory technique cannot correct a specimen collected from the wrong patient.

120. Pre-Analytical Errors

Pre-analytical errors occur before the specimen reaches the testing phase. They are among the most dangerous errors in transfusion medicine because they may involve the wrong patient or wrong specimen.

121. Common Pre-Analytical Errors

Error Possible Consequence Prevention
Wrong patient identified Incorrect ABO result assigned to another patient Use at least two independent patient identifiers
Specimen labeled away from the patient Wrong-blood-in-tube event Label immediately at the bedside or collection site
Missing or incomplete patient identifiers Specimen cannot be reliably linked to the patient Reject specimens that fail identification requirements
Anti-A,B reagent Expected reactivity with A, B, and O control cells Repeat QC using fresh controls and verify reagent performance
A1 reagent cells Expected reaction with known anti-A plasma or serum Replace cells if reactivity, appearance, or expiry is unacceptable
B reagent cells Expected reaction with known anti-B plasma or serum Repeat QC and replace reagent cells if necessary
O reagent cells Expected absence of A and B antigen-related reactions Investigate contamination, labeling error, or unexpected antibody
Anti-A1 lectin Positive with A1 cells and negative with A2 cells Do not use until acceptable positive and negative controls are obtained
Anti-H lectin Strong reaction with Group O cells and no reaction with Bombay cells when available Verify reagent storage, controls, and expiry before patient testing
Reagent cell appearance No hemolysis, contamination, discoloration, or excessive clumping Discard unacceptable cells and open a new vial
Centrifuge Validated speed, time, brake function, and maintenance status Stop testing and verify performance before reuse
Incubator or heat block Temperature within the validated range Quarantine affected tests and repeat after correction
Automated blood bank analyzer Daily controls, background checks, alarms, and maintenance status Follow instrument troubleshooting and repeat patient testing as required
Laboratory information system Correct patient interface, result transfer, compatibility rules, and alerts Use downtime procedures and report the issue to authorized personnel

136. Positive and Negative Controls

Blood grouping reagents should be evaluated with control cells known to express or lack the relevant antigen. Controls confirm that the reagent is capable of producing the expected positive reaction and does not cause nonspecific agglutination with antigen-negative cells.

Reagent Suggested Positive Control Suggested Negative Control
Anti-A Known Group A cells Known Group B or O cells
Anti-B Known Group B cells Known Group A or O cells
Anti-A,B Known Group A and Group B cells Known Group O cells
Anti-D Known RhD-positive cells Known RhD-negative cells
Anti-A1 Lectin Known A1 cells Known A2 cells
Anti-H Lectin Known Group O cells H-deficient cells when available or another validated negative control
Control Selection

Control cells must be appropriate for the reagent, method, and intended clinical use. The laboratory should follow manufacturer instructions and its validated quality-control procedure.

137. Reagent Management

Reagent quality directly affects ABO typing accuracy. All antisera, reagent cells, lectins, enhancement media, and antiglobulin reagents must be stored, handled, and monitored according to validated requirements.

138. Reagent Acceptance Checklist

  • Verify manufacturer, product name, lot number, and expiry date.
  • Inspect packaging for leakage, breakage, or transport damage.
  • Confirm transport temperature where required.
  • Review the certificate of analysis when applicable.
  • Perform lot-to-lot comparison before routine use.
  • Perform positive and negative control testing.
  • Document date received, date opened, and date placed into service.
  • Assign storage location and temperature requirements.
  • Record the initials or identification of the person accepting the reagent.

139. Reagent Storage Errors

Storage Problem Possible Effect Required Action
Temperature excursion Reduced reagent potency or accelerated deterioration Quarantine reagent and assess excursion according to policy
Freezing of liquid antisera Protein precipitation or altered performance Do not use unless manufacturer evaluation confirms acceptability
Prolonged exposure to heat Weak or false-negative reactions Discard or quarantine and perform documented investigation
Cap left open Evaporation, contamination, or concentration change Discard reagent if integrity is uncertain
Dropper contamination Cross-contamination between reagents Discard affected reagent and review technique
Incorrect refrigerator placement Exposure to unstable temperature zones Store in monitored, validated locations

140. Equipment Quality Control

Reliable ABO testing requires equipment that is suitable, calibrated, maintained, and monitored. Equipment failure can create systematic errors affecting multiple patient results.

Centrifuges

  • Verify revolutions per minute or relative centrifugal force.
  • Check timer accuracy.
  • Inspect buckets and tube holders.
  • Document preventive maintenance.
  • Clean spills promptly.

Refrigerators

  • Monitor temperature continuously or at defined intervals.
  • Review alarms and excursion records.
  • Maintain adequate air circulation.
  • Avoid overloading shelves.
  • Perform alarm and backup power checks.

Pipettes

  • Inspect for leakage and damage.
  • Verify volume accuracy.
  • Calibrate at scheduled intervals.
  • Use compatible tips.
  • Clean according to procedure.

Automated Analyzers

  • Perform startup controls.
  • Review error flags.
  • Inspect fluid levels and waste containers.
  • Complete scheduled maintenance.
  • Validate software and hardware updates.

141. Tube Method Errors

Tube Method Error Result Effect Prevention
Tubes not labeled before testing Specimen or reagent mix-up Label each tube before adding material
Incorrect order of reagent addition Omission may not be recognized Use a standardized sequence
Cell suspension too heavy Weak antibodies may be missed Use a validated cell concentration
Cell suspension too light Reaction may appear falsely strong or unstable Prepare cells consistently
Incorrect centrifugation False-positive or false-negative reaction Use validated centrifuge settings
Cell button shaken too strongly Weak agglutinates may be destroyed Resuspend gently
Reaction not observed immediately Drying or delayed artifacts Read within the defined time

142. Gel Card and Column Agglutination Errors

Column agglutination technology improves standardization but remains vulnerable to specimen, reagent, instrument, and interpretation errors.

Error Possible Appearance Corrective Action
Incorrect cell concentration Weak, overloaded, or difficult-to-read column Prepare cells using the specified diluent and concentration
Air bubbles in microcolumn Irregular cell distribution Load samples carefully and repeat if interpretation is uncertain
Card not brought to required temperature Unexpected weak or variable reactions Follow manufacturer equilibration instructions
Expired or dehydrated gel card Abnormal migration or unreliable reaction Discard the card
Incorrect centrifugation program False reaction distribution Repeat using the validated program
Fibrin or clots in sample Cells trapped at the top of the column Inspect specimen and repeat with an acceptable sample
Overfilling wells Spillage or cross-contamination Use calibrated pipettes and specified volumes
Reader interpretation error Incorrect grade or missed mixed-field pattern Review manually and repeat when needed

143. Solid-Phase Testing Errors

  • Incorrect plasma or reagent-cell volume.
  • Incomplete washing of test wells.
  • Failure to remove residual wash solution.
  • Contamination of wells.
  • Incorrect incubation time or temperature.
  • Reader or image-analysis error.
  • Carryover between samples.
  • Failure to recognize nonspecific adherence.
Platform-Specific SOP

Reaction patterns are not interpreted identically across tube, gel, microplate, and solid-phase methods. Staff must be trained and assessed on the specific platform used in their laboratory.

144. Managing Automated Analyzer Flags

Automated blood bank systems may flag weak reactions, mixed-field patterns, double populations, imaging uncertainty, sample volume problems, or instrument errors. Flags must be reviewed by qualified personnel.

145. Recommended Flag Review Process

  1. Review the instrument-generated image or reaction pattern.
  2. Check sample identity and sample quality.
  3. Review reagent lot, expiry, and QC status.
  4. Repeat the test using the same method when appropriate.
  5. Repeat by an alternative method when the result remains unclear.
  6. Compare current results with historical blood group records.
  7. Investigate any ABO discrepancy before validation.
  8. Document manual review and final interpretation.
Automation Does Not Replace Professional Review

An analyzer-generated blood group must not be released when flags, discrepancies, or unusual reaction patterns remain unresolved.

146. Repeat Testing and Duplicate Testing

Repeat testing may be required when reactions are weak, inconsistent, unexpected, technically invalid, or inconsistent with previous records. However, repeating the same error-prone procedure without investigating the cause may reproduce the same incorrect result.

147. When Repeat Testing Is Appropriate

  • Reagent or specimen was omitted.
  • Reaction is unclear or mixed-field.
  • Instrument generated an interpretation flag.
  • Current ABO group differs from the historical group.
  • Control results are unacceptable.
  • Technical error is suspected.
  • Specimen contamination is possible.
  • Forward and reverse grouping disagree.

148. When a New Specimen Is Required

  • Patient identity is uncertain.
  • The specimen is mislabeled or unlabeled.
  • Wrong-blood-in-tube is suspected.
  • The specimen is unsuitable for testing.
  • The current result differs significantly from history without explanation.
  • The sample is outside the validated validity period.

149. Corrective and Preventive Action

Corrective action addresses the immediate problem and restores safe testing. Preventive action reduces the chance that the same error will happen again.

Problem Immediate Correction Corrective Action Preventive Action
Expired reagent used Stop testing and repeat affected samples Identify all affected results and assess patient impact Improve inventory alerts and expiry checks
Incorrect centrifuge setting Correct setting and repeat testing Review previously tested samples during the affected period Lock programs and perform scheduled verification
Mislabeled specimen Reject specimen and request recollection Report the incident and investigate collection workflow Strengthen bedside identification and barcode processes
ABO result entered incorrectly Correct the report and notify affected users Assess whether blood was selected or issued incorrectly Use analyzer-LIS interfaces and independent verification
Unacceptable reagent QC Quarantine reagent and repeat QC Repeat patient testing performed after the last acceptable QC Improve daily QC review and lot acceptance procedures

150. Root Cause Analysis

Root cause analysis aims to identify why an error occurred rather than blaming the individual who discovered or committed the error. Effective investigation considers workflow, equipment, environment, communication, training, and system design.

151. Five Whys Example

Problem: A specimen was labeled with the wrong patient's details.
Why 1: The collector used a label belonging to another patient.
Why 2: Labels for several patients were printed together.
Why 3: The collection process permitted batch printing.
Why 4: Bedside barcode printing was not available.
Why 5: The risk of batch labeling had not been formally assessed.
Root Cause: The workflow allowed labels to be separated from the patient-identification process.
Quality Pearl

“Staff must be more careful” is rarely an adequate preventive action. Effective action changes the process so that the error is harder to make and easier to detect.

152. Risk Management in ABO Testing

Risk management identifies hazards, estimates their likelihood and severity, and introduces controls to reduce patient harm.

153. Example Risk Matrix

Hazard Likelihood Severity Overall Risk Recommended Control
Wrong patient specimen Possible Catastrophic High Two identifiers, bedside labeling, second ABO sample
Expired reagent Unlikely Major Medium Electronic inventory alerts and daily checks
Weak subgroup missed Rare Major Medium Discrepancy algorithm and reference testing
Transcription error Possible Catastrophic High Direct LIS interface and independent confirmation
Minor centrifuge variation Possible Low to Moderate Low Routine equipment verification

154. Failure Mode and Effects Analysis

Failure Mode and Effects Analysis is a proactive method used to examine each step of a process, identify how it could fail, and prioritize improvements before patient harm occurs.

Process Step Potential Failure Mode Potential Effect Existing Control Additional Improvement
Patient identification Wrong wristband checked Wrong-blood-in-tube Two identifiers Barcode scanning with positive patient confirmation
Specimen labeling Tube labeled away from patient Patient-sample mismatch Collection policy Bedside label printing and electronic lockout
Manual testing Reagent omitted False-negative result Worksheet sequence Automated pipetting or independent check
Result validation Discrepancy overlooked Incorrect ABO report Technologist review LIS rule blocking incompatible forward and reverse results
Blood issue Wrong unit selected ABO-incompatible transfusion Manual comparison Barcode-controlled electronic issue

155. Incident Reporting

Errors, near misses, unexpected events, and unsafe conditions should be reported through the laboratory quality system. Near misses are especially valuable because they reveal weaknesses before patient harm occurs.

156. Information to Include in an Incident Report

  • Date and time of the event.
  • Location and stage of the process.
  • Patient identifiers according to privacy policy.
  • Specimen and blood component details.
  • Description of what happened.
  • How the event was detected.
  • Immediate action taken.
  • Whether the patient was affected.
  • Individuals notified.
  • Root cause investigation findings.
  • Corrective and preventive actions.
  • Effectiveness review date.

157. Near-Miss Examples

Near Miss 1

A tube labeled with the wrong patient's details was detected before testing because the date of birth did not match the request.

Near Miss 2

An ABO-incompatible unit was selected but blocked by the electronic compatibility system before issue.

Near Miss 3

A historical anti-K alert prevented electronic crossmatch and triggered selection of K-negative red cells.

Near Miss 4

A forward and reverse grouping discrepancy was identified during final validation before the blood group was released.

Safety Culture

Near-miss reporting should be encouraged and non-punitive. The goal is to improve systems, strengthen controls, and prevent future patient harm.

158. Documentation Requirements

Complete documentation supports traceability, clinical decision-making, quality review, regulatory compliance, and investigation of adverse events.

159. Essential ABO Testing Records

  • Patient identifiers.
  • Specimen collection date and time.
  • Collector identification where required.
  • Specimen receipt date and time.
  • Forward grouping results and reaction grades.
  • Reverse grouping results and reaction grades.
  • RhD typing result and control result where applicable.
  • Reagent manufacturer, lot number, and expiry.
  • Testing method and instrument identification.
  • Technologist identification.
  • Discrepancy investigation results.
  • Final interpretation.
  • Corrective actions.
  • Blood component selection decision.
  • Senior review or medical authorization when required.

160. Competency Assessment

Personnel performing ABO testing must receive initial training and periodic competency assessment. Competency should evaluate knowledge, practical skills, problem-solving ability, documentation, and adherence to safety procedures.

161. Suggested Competency Elements

Competency Element Example Assessment
Direct observation Observe specimen handling, reagent use, and reaction grading
Result recording Review worksheets, analyzer records, and LIS entries
Instrument maintenance Observe completion of daily and scheduled maintenance
Quality-control performance Evaluate control interpretation and corrective action
Unknown specimen testing Provide blinded samples with normal and discrepant reactions
Problem-solving Present a clinical scenario involving weak or mixed-field reactions

162. Proficiency Testing

External proficiency testing evaluates the laboratory's ability to obtain correct results on unknown samples and compare performance with peer laboratories.

163. Proficiency Testing Rules

  • Test proficiency samples in the same manner as patient samples.
  • Use routine personnel and routine methods.
  • Do not refer samples to another laboratory unless specifically permitted.
  • Document all testing steps and interpretations.
  • Investigate every unacceptable result.
  • Implement corrective action and verify effectiveness.

164. ABO Testing Audit Checklist

  • Are patient identifiers complete and consistent?
  • Are specimens labeled at the collection site?
  • Are acceptance and rejection criteria documented?
  • Are current and historical ABO results compared?
  • Are forward and reverse grouping both performed when appropriate?
  • Are discrepancies blocked from automatic release?
  • Are reagent lot numbers and expiry dates traceable?
  • Are daily quality-control records complete?
  • Are temperature records reviewed?
  • Are centrifuges and pipettes calibrated?
  • Are analyzer flags reviewed and documented?
  • Are corrective actions recorded?
  • Are staff competencies current?
  • Are incidents and near misses analyzed?
  • Are electronic compatibility rules validated?

165. Practical Error-Resolution Cases

Case 1: Current Group Differs from Historical Record

Historical result: Group A RhD Positive

Current result: Group O RhD Positive

Required response: Stop reporting, verify specimen identity, recollect a second specimen, review transfusion and transplantation history, and investigate possible wrong-blood-in-tube or mixed red cell populations.

Case 2: Reverse Grouping Shows Unexpected Panreactivity

Forward group: Group A

Reverse group: Reactions with A1 cells, B cells, and O cells

Possible causes: Cold autoantibody, rouleaux, or another unexpected antibody.

Recommended testing: Autocontrol, saline replacement, antibody screen, prewarming where validated, and review of clinical history.

Case 3: Weak Forward Grouping in a Leukemia Patient

Anti-A: 1+

Anti-B: 0

Reverse grouping: Expected Group A pattern

Interpretation: Reduced A antigen expression associated with hematologic disease may be present. Repeat testing, use anti-A,B, review previous results, and consider additional subgroup studies.

Case 4: Apparent Positive Reaction in Every Tube

Forward grouping: Anti-A positive, Anti-B positive, control positive

Autocontrol: Positive

Interpretation: The positive control indicates that the forward grouping cannot be interpreted directly. Cold autoagglutination or spontaneous red cell aggregation should be investigated.

166. Practical Laboratory Pearls

Pearl 1

The safest response to uncertain specimen identity is recollection, not relabeling.

Pearl 2

An ABO discrepancy is a safety warning, not an inconvenience to be bypassed.

Pearl 3

A positive reagent control invalidates interpretation of the associated patient reactions.

Pearl 4

Repeating a test is useful only when the possible source of error is identified and corrected.

Pearl 5

Automation reduces some manual errors but creates new risks involving data interfaces, software rules, and incorrect automatic validation.

Pearl 6

Every corrected result should include an assessment of whether any blood component was selected, issued, or transfused using the incorrect result.

Suggested Image: ABO Testing Error Prevention Workflow Create a professional WebP infographic showing pre-analytical, analytical, and post-analytical errors with prevention steps and laboratory checkpoints.
Suggested Image: ABO Discrepancy Troubleshooting Algorithm Show specimen verification, repeat testing, history review, additional serologic tests, reference laboratory referral, and final reporting.

167. Quick Revision Box

  • Wrong patient identification is one of the most dangerous transfusion errors.
  • Unlabeled and mislabeled specimens should generally be rejected.
  • Forward and reverse grouping must agree before routine final reporting.
  • Incorrect cell concentration can cause false reactions.
  • Undercentrifugation may weaken reactions.
  • Overcentrifugation may mimic agglutination.
  • Rouleaux usually disappears after saline replacement.
  • True agglutination usually remains after saline replacement.
  • Unacceptable quality control invalidates patient testing.
  • Automated analyzer flags require qualified review.
  • Corrective action fixes the immediate problem.
  • Preventive action reduces recurrence.
  • Near misses should be reported and investigated.
  • Documentation must provide complete traceability.
  • Staff competency must include practical problem-solving.

168. Suggested Image ALT Text

ABO testing errors image:
Pre-analytical, analytical, and post-analytical errors in ABO blood group testing with laboratory prevention and corrective-action steps.

Specimen rejection image:
Blood bank specimen rejection criteria showing unlabeled, mislabeled, clotted, insufficient, leaking, and expired blood samples.

Rouleaux image:
Microscopic comparison of rouleaux coin-stack formation and true red blood cell agglutination in blood bank testing.

Quality-control image:
ABO blood grouping quality-control checklist covering reagents, reagent cells, centrifuges, pipettes, refrigerators, analyzers, and laboratory information systems.

Risk-management image:
Medical laboratory risk matrix showing likelihood, severity, controls, corrective action, and preventive action in ABO blood typing.

169. Key Take-Home Messages

  • Patient identification is the foundation of safe ABO testing.
  • A technically perfect test can still be dangerous when performed on the wrong specimen.
  • Pre-analytical errors often have the greatest potential for catastrophic harm.
  • Analytical procedures must use validated reagents, equipment, and methods.
  • Post-analytical review must detect discrepancies and prevent incorrect reporting.
  • Unresolved ABO discrepancies must block routine group-specific blood issue.
  • Quality-control failure requires investigation of affected patient testing.
  • Automated testing does not eliminate the need for professional interpretation.
  • Corrective and preventive action should address the true root cause.
  • Near-miss reporting strengthens transfusion safety.
  • Complete documentation supports traceability and patient protection.
  • Ongoing competency assessment is essential for all blood bank personnel.

Ten advanced ABO clinical case studies covering weak subgroups, Bombay phenotype, acquired B, mixed-field reactions, neonatal testing, rouleaux, cold autoantibodies, stem cell transplantation, massive transfusion, and transfusion-reaction investigation.

Medical and Educational Disclaimer: This content is intended for education and professional development. It does not replace institutional SOPs, validated manufacturer instructions, national transfusion requirements, regulatory standards, reference laboratory consultation, or clinical judgment.

Prepared by

Dr. Omar Adwan
Medical Laboratory Technologist
Founder of MedLab Academy

Dedicated to advancing medical laboratory education through practical, evidence-based, and clinically relevant learning resources.

Mismatch between request form and specimen

Edit This Article
Tags

You may like these posts

Comments